Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 11/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802688 | 1.00 | LSS (0.45) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4803673 | 0.90 | LSS (0.46) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4803666 | 0.90 | LSS (0.46) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4803991 | 0.89 | LSS (0.49) | LSSMAPTKMT2A | |
| SCHEMBL4803995 | 0.89 | LSS (0.49) | LSSMAPTKMT2A | |
| SCHEMBL4799620 | 0.88 | LSS (0.52) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4805067 | 0.88 | LSS (0.52) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4799618 | 0.88 | LSS (0.52) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4805073 | 0.88 | LSS (0.52) | LSSLMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL7209307 | 0.88 | SMN1; SMN2 (0.47) | LMNAMAPTKMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885LMNA 2735/4885MAPT 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.